Shah Capital has urged Novavax’s (NVAX) board to pursue a sale of the biotech, citing a third consecutive year of poor roll-out of its COVID-19 shot, the hedge fund said on Tuesday, Reuters’ Sneha S K and Bhanvi Satija reports. In its letter, shared exclusively with Reuters, the company’s second largest shareholder recommended that Novavax’s capabilities will “have far greater potential in the hands of a large capable pharma entity.” Shah Capital owns a 7.2% stake in Novavax, the authors note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax Transfers EU Vaccine Rights to Sanofi
- Novavax’s Nuvaxovid EU approval triggers $25M milestone payment from Sanofi
- Unusually active option classes on open October 2nd
- Novavax announces progress on Sanofi agreement
- Challenging Market Dynamics and Regulatory Hurdles Lead to Sell Rating for Novavax